Informations sur le produit
- 1,1'-((Methylethanediylidene)dinitrilo)diguanidine
- 2,2′-(1-Methyl-1,2-ethanediylidene)bis[hydrazinecarboximidamide]
- Ai3-60317
- Brn 1912590
- Guanidine, 1,1'-((methylethanediylidene)dinitrilo)di-
- Hydrazinecarboximidamide, 2,2'-(1-methyl-1,2-ethanediylidene)bis- (9CI)
- Hydrazinecarboximidamide, 2,2′-(1-methyl-1,2-ethanediylidene)bis-
- Me-GAG
- Methyl-G
- Methyl-Gag
- Voir d'autres synonymes
- Methylglyoxal bis(amidinohydrazone)
- Methylglyoxal bis(guanylhydrazone)
- Mitoguanazone
- Mitoguazona
- Mitoguazona [INN-Spanish]
- Mitoguazone [INN:DCF]
- Mitoguazonum
- Mitoguazonum [INN-Latin]
- N''-{(1E,2E)-2-[(diaminomethylidene)hydrazono]-1-methylethylidene}carbonohydrazonic diamide (non-preferred name)
- NSC 32946
- Pyruvaldehyde bis(amidinohydrazone)
- Unii-Od5Q0L447W
Mitoguazone is a drug that inhibits the synthesis of methylglyoxal, a reactive dicarbonyl compound that can cause cellular injury. Mitoguazone has been shown to inhibit mitochondrial functions and cell death in neurons. Mitoguazone also inhibits the production of polyamines, which are involved in tumor growth and metastasis. Mitoguazone has been shown to have anti-cancer properties in model systems. Analytical methods for mitoguazone include high-performance liquid chromatography with ultraviolet detection and gas chromatography with flame ionization detection.